This landmark research and trial was led by Professor Stephen Nicholls, Director of the Monash University’s Victorian Heart Institute and Victorian Heart Hospital and presented at the European Society of Cardiology Congress in Amsterdam and published in
(a), known as Lp(a) or spoken as ‘LP little a’, impact one in five people globally with no approved treatment currently on the market.
The trial demonstrated the success of Muvalaplin – the first oral drug ever developed to target Lp(a) – effectively lowering levels by up to 65%. It works by disrupting the ability of Lp(a) to form in the body.
Lp(a) is similar to LDL cholesterol, sometimes called ‘bad cholesterol‘, but is more sticky, increasing the risk of blockages and blood clots in arteries. Common LDL-lowering drugs such as statins don’t have the same lowering effect on Lp(a). Being largely genetic, Lp(a) is also difficult to control through diet, exercise and other lifestyle changes.
Although Lp(a) was discovered nearly 60 years ago there still aren’t any widely accessible treatments available to lower levels and reduce cardiovascular risk.
Professor Nicholls said the global research industry has been working on a targeted solution to treat elevated Lp(a) for the past decade, but advancements so far have made it difficult to administer injection-based therapies that are not yet on the market.
“When it comes to treating high Lp(a), a known risk factor for cardiovascular disease, our clinicians currently have no effective tools in their kit,” Professor Nicholls said.”Lp(a) is essentially a silent killer with no available treatment, this drug changes that.”
The trial was undertaken in collaboration with Cleveland Clinic and Eli Lilly, the drug will now continue into larger phase clinical trials. It may also have the potential to be used in the treatment of other vascular and valve diseases.
- Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) FormationA Randomized Clinical Trial- (https://jamanetwork.com/journals/jama/fullarticle/2808864)